Financial Performance: iRadimed Corp reported record revenues of $20.4 million for Q2 2025, a 14% increase year-over-year, with strong gross profit margins and an increase in GAAP diluted earnings per share by 18%. The company raised its full-year revenue guidance to $80-$82.5 million.
Product Launch and Market Outlook: The successful launch of the new 3,870 IV pump system is expected to drive future sales, although there may be short-term operational inefficiencies due to facility transitions and low initial bookings anticipated in Q1 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Wall Street analysts forecast IRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast IRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 99.180
Low
98.00
Averages
99.00
High
100.00
Current: 99.180
Low
98.00
Averages
99.00
High
100.00
Roth Capital
Buy
maintain
$90 -> $98
2025-11-04
Reason
Roth Capital
Price Target
$90 -> $98
AI Analysis
2025-11-04
maintain
Buy
Reason
Roth Capital raised the firm's price target on iRadimed to $98 from $90 and keeps a Buy rating on the shares after its Q3 earnings beat. Legacy pump sales remain strong despite the planned full launch of the next generation version in Q1, monitor sales accelerated in the quarter, and there could be nice uplift from the cross-selling the next gen pump into non-user hospitals, the analyst tells investors in a research note.
Lake Street
Buy
maintain
$75 -> $100
2025-11-03
Reason
Lake Street
Price Target
$75 -> $100
2025-11-03
maintain
Buy
Reason
Lake Street raised the firm's price target on iRadimed to $100 from $75 and keeps a Buy rating on the shares after a top and bottom line beat with revenue and EPS guidance increased in Q3. While acknowledging that shares trade at a premium valuation, the firm sees a record backlog providing near-term visibility and the new 3870 IV Pump launch driving growth acceleration in 2026, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IRMD
Unlock Now
About IRMD
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Transcript of IRadimed (IRMD) Earnings Call for Q3 2025
Nov 28 2025NASDAQ.COM
Author's Perspective: The views and opinions presented are solely those of the author.
No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Continue Reading
Upcoming Ex-Dividend Dates for Duke Energy, American States Water, and iRadimed
Nov 12 2025NASDAQ.COM
Upcoming Ex-Dividend Dates: Duke Energy Corp (DUK), American States Water Co (AWR), and iRadimed Corp (IRMD) will trade ex-dividend on 11/14/25, 12/2/25, and 11/25/25 respectively, with dividends of $1.065, $0.504, and $0.17.
Expected Price Adjustments: Following the ex-dividend dates, shares of DUK, AWR, and IRMD are expected to open lower by approximately 0.86%, 0.66%, and 0.20% respectively.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 3.44% for Duke Energy, 2.66% for American States Water, and 0.80% for iRadimed, reflecting their historical dividend stability.
Current Trading Performance: As of Wednesday trading, Duke Energy shares are up 0.6%, American States Water shares are up 1.1%, while iRadimed shares are down 1.7%.
Continue Reading
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?
How does the company's performance compare to its main competitors in the same sector?